Variables | SPATS2L expression | P value | |
---|---|---|---|
Low group | High group | ||
Number, n (%) | 111 (50%) | 111 (50%) | Â |
Age, median(range) | 46 (15,80) | 52 (14,82) | 0.012 |
Female, n (%) | 45 (40.5) | 56 (50.5) | 0.178 |
WBC1, median(range) | 21.70 (0.2,453.2) | 20.8 (0.7,229.90) | 0.284 |
HB2, median(range) | 85.0 (33.5,141.0) | 80.0 (37.4,135) | 0.090 |
PLT3, median(range) | 33 (2,556) | 62 (4,778) | 0.001 |
BM4 blast, median(range)% | 70 (20,98) | 69 (17.5,96.65) | 0.810 |
FAB5 type | Â | Â | 0.037 |
 M0 | 8 (7.2) | 13 (11.7) |  |
 M1 | 17 (15.3) | 8 (7.2) |  |
 M2 | 53 (47.7) | 40 (36.0) |  |
 M4 | 6 (5.4) | 5 (4.5) |  |
 M5 | 23 (20.7) | 40 (36) |  |
 M6 | 2 (1.8) | 4 (3.6) |  |
Karyotype risk6, n (%) | Â | Â | 0.154 |
 Favorable | 3 (2.7) | 2 (1.8) |  |
 Intermediate | 96 (80.5) | 104 (93.7) |  |
 Unfavorable | 7 (16.3) | 2 (1.8) |  |
Gene mutation | |||
 FLT3-ITD | 18 (16.2) | 26 (23.4) | 0.239 |
 NPM1 | 24 (21.6) | 38 (34.2) | 0.052 |
 CEBPADM7 | 19 (17.1) | 13 (11.7) | 0.122 |
 IDH1 | 5 (4.5) | 14 (12.6) | 0.053 |
 IDH2 | 9 (8.1) | 12 (10.8) | 0.647 |
 DNMT3A | 7 (6.3) | 16 (14.4) | 0.076 |
Treatment protocols8 | Â | Â | 0.352 |
 DA or IA | 82 (76.6) | 73 (70.2) |  |
 HAA | 25 (23.4) | 30 (28.8) |  |
Clinical event | |||
 Complete remission rate (%) | 85 (81.7) | 74 (73.3) | 0.181 |
 Relapse rate (%) | 21 (25) | 39 (52.7) | 0.001 |
 Death rate (%) | 41 (36.9) | 57 (52.3) | 0.03 |